Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights.
Boehringer Ingelheim’s Cyltezo has a slight competitive edge over other concurrent biosimilar launches on certain key performance metrics, though prescriber future projections show little differentiation in use among the recent entrants. Exton, PA, September 14, 2023 — This summer ushered in the highly anticipated introduction of a multitude of additional adalimumab biosimilars to the dynamic […]
Amgen tipped to keep Otezla market share in fight with BMS’ Sotyktu, leaving opportunity for J&J
Amgen’s $13.4 billion Otezla bet can withstand competition from Bristol Myers Squibb’s Sotyktu. That is the conclusion of analysts at Spherix Global Insights, who found Amgen is holding on to its market share and largely limiting BMS’ growth to the conversion of users of injectable biologics. BMS sold Otezla to Amgen to secure regulatory clearance for […]
With Little Remaining Unmet Need for Injectable Biologics for the Treatment of Plaque Psoriasis, US Dermatologists Report the Future is Oral, According to Spherix Global Insights
Despite the increased efficacy of BMS’ Sotyktu over Amgen’s Otezla, dermatologists continue to express a desire for additional oral agents that bring enhanced safety and efficacy. Exton, PA August 31, 2023 – The biologic treatment armamentarium for plaque psoriasis has arguably experienced some of the most successful developments in recent autoimmune history. With the entry […]
Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata
After early adoption, overall use of Olumiant in alopecia areata is beginning to level-off, according to Spherix Global Insights Exton, PA, July 11, 2023 – In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia areata (AA). At one-year post approval, perceptions of the […]
COVID-19 Wreaking Havoc in Specialty Practices and the Vast Majority of Physicians Expect It to Get Worse in the Next Two Weeks, According to a New Report by Spherix Global Insights
Results from a survey of more than 300 dermatologists, gastroenterologists, nephrologists, neurologists, rheumatologists, and primary care physicians indicate a marked decrease in patient visits, growing concern over financial impact to practices, and worry over preparedness for a widespread local outbreak EXTON, Pa., March 24, 2020 / PRNewswire / – Spherix Global Insights is an independent […]
US Dermatologists Anticipate the Future of Atopic Dermatitis to Mirror that of the Over-Crowded Psoriasis Market
With a plethora of agents in development, manufacturers who already have one leg in the dermatology biologic/small molecule space, such as AbbVie, Amgen, Eli Lilly, Janssen, and Novartis could have a competitive edge over more novel developers. EXTON, Pa., March 17, 2020 /PRNewswire/ — The past decade has ushered in an array of new treatment […]
Sanofi/Regeneron’s Dupixent Continues to Flourish as the Only Atopic Dermatitis Game in Town, but US Dermatologists Identify a Gap Between Current Patients and Candidates for Treatment
With Dupixent only capturing a piece of the potential candidate pie, there remains ample runway for new agents in development to enter this highly dynamic market. Download Report Overview EXTON, Pa., Nov. 7, 2018 /PRNewswire/ – After over a year and a half on the market, U.S. dermatologists (n=102) remain extremely pleased with Sanofi/Regeneron’s Dupixent. In Spherix’s fourth quarter […]
Analysis of Over 1,000 Atopic Dermatitis Patients Highlights Moderate-to-Severe Patient Candidacy for Biologics and Small Molecules and Real-World Treatment Patterns for Patients Treated With Sanofi/Regeneron’s Dupixent
Candidacy analysis for pipeline agents reveals that JAK inhibitors, such as Pfizer’s PF-0496582, AbbVie’s upadacitinib and Incyte’s topical ruxolitinib have the most potential upside if approved Download Report Overview EXTON, Pa., September 27, 2018 (Newswire.com) – To better understand what real-world moderate and severe atopic dermatitis patients look like in terms of disease burden, physician […]
US Dermatologists Delighted with Sanofi/Regeneron’s Dupixent, but Increased Familiarity and Experience with Pfizer’s Eucrisa May be Breeding Contempt
According to a recent study conducted by Spherix Global Insights, US dermatologists (n=104) report significantly higher satisfaction with Dupixent than with any of the other approved agents for the treatment of atopic dermatitis, while Eucrisa garners the lowest satisfaction ratings. Download Report Overview EXTON, Pa., Nov. 30, 2017 /PRNewswire/ — The most recent release of […]
Dermatologists’ Six Month Projections Reveal Janssen’s Tremfya Closing in on the IL-17 Inhibitors, Novartis’ Cosentyx and Eli Lilly’s Taltz, in Psoriasis
According to Spherix Global Insights’ latest quarterly release of RealTime Dynamix™: Psoriasis, adoption of Tremfya as a psoriasis treatment is largely comparable to that of Taltz’s at a similar post-launch timeframe. Download Report Overview EXTON, Pa., Nov. 29, 2017 /PRNewswire/ — At approximately four months post-launch, over one-third of surveyed dermatologists (n=101) have prescribed Tremfya, […]
